Remarks

I.   Summary of the Office Action

In the Office Action dated January 30, 2009, the Examiner has withdrawn the objection to claims 42 and 52 and the rejection of claims 42-44 and 52-53 under 35 U.S.C. § 102(b) over Eisenbach-Schwartz *et al.* (US 2002/0072493 A1). The Examiner has maintained the rejections under 35 U.S.C. § 112, second paragraph, and 35 U.S.C. § 103(a).

II.   Rejection Under 35 U.S.C. § 112, Second Paragraph, is Traversed

In section 3 of the Office Action at pages 2-6, the Examiner has maintained the rejection of claims 42-47, 49-56, and 58-60 under 35 U.S.C. § 112, second paragraph, for allegedly being indefinite. In particular, the Examiner maintains that the phrase "eight leucine-rich repeats" as used in claims 42 and 52 is unclear. Applicants respectfully disagree and traverse this rejection.

Applicants submit that claims 42 and 52 are not indefinite and would be clearly understood by a person skilled in the art. The Examiner, however, contends that the phrase eight leucine-rich repeats is indefinite because "the specification does not describe what 8 LRRs are and where these are located." *See* Office Action at page 3. The Examiner maintains that it is unclear if eight leucine-rich repeats means "a sequence of 'LLLLLLLL'" or that "8 leucine residues would encompass 1 leucine-rich region." *Id.* at page 3. In particular, the Examiner has asserted that there are leucine residues throughout SEQ ID NOs:1-3 disclosed in the specification and that even in view of teachings of Kobe, B., and Kajava, A.V., *Current Opinion in Structural Biology* 11:725-

32 (2001) ("Kobe and Kajava"), submitted in the Amendment and Reply Under 37

C.F.R. § 1.111, dated November 6, 2008, "[i]t is still unclear where the 8 leucine-rich

repeats are located in the sequence." *Id.* at page 5. The Examiner has also asserted that

because it is allegedly unclear where the eight leucine-rich repeats are located in the

disclosed sequences, it is unclear where the LRRCT domain is located. *Id.* at pages 5-6.

Applicants respectfully assert that the Examiner's maintained focus on the

definiteness of eight leucine-rich repeats is misplaced, and that the proper inquiry under

35 U.S.C. § 112, second paragraph, is consideration of "the claim as a whole to

determine whether the claim apprises *one of ordinary skill in the art* of its scope."

M.P.E.P. § 2173.02 (emphasis added). M.P.E.P. § 2173.02 states:

> The essential inquiry pertaining to this requirement is whether the claims
> set out and circumscribe a particular subject matter with a reasonable
> degree of clarity and particularity. Definiteness of claim language must
> be analyzed, not in a vacuum, but in light of:
>   (A) The content of the particular application disclosure;
>   (B) The teachings of the prior art; and
>   (C) The claim interpretation that would be given by one possessing
> the ordinary level of skill in the pertinent art at the time the invention was
> made.

Id. (emphasis added). In view of this framework, Applicants assert that claims 42 and 52

set out and circumscribe the subject matter claimed therein with a reasonable degree of

clarity and particularity.

(A) The content of the particular application disclosure. Claims 42 and 52

require that the soluble Nogo receptor-1 polypeptide comprises an NT domain, eight

leucine-rich repeats, and an LRRCT domain. As the Examiner points out, the

specification discloses that "[f]ull-length Nogo receptor-1 consists of a signal sequence, a

N-terminus region (NT), eight leucine-rich repeats (LRR), a LRRCT region (a leucine-

rich-repeat domain C-terminal of the eight leucine-rich repeats), a C-terminus region

(CT) and a GPI anchor." *See* specification at page 7, lines 19-22. The specification also

discloses the polypeptide sequences of, *e.g.*, human and rat Nogo receptor-1. *See id.* at

Table 1. Thus, the specification discloses the polypeptide sequences of human and rat

Nogo receptor-1, that full-length Nogo receptor-1 has eight leucine-rich repeats, and that

C-terminal to those eight leucine-rich repeats, there is an additional leucine-rich repeat

domain.

(B) The teachings of the prior art. As described in the Amendment and Reply

Under 37 C.F.R. § 1.111, dated November 6, 2008, two references available at the time

of the invention, PCT/US02/32007 and PCT/US03/25004, which were incorporated by

reference in their entireties in the present specification, describe additional soluble Nogo

receptor-1 polypeptides that may be used in the methods of the invention. *See*

specification at page 8, lines 9-11. These international applications, which illustrate the

state of the art, also provide amino acid sequences and schematic representations of the

domains of a Nogo receptor and show representative examples of the eight leucine-rich

repeats present in Nogo receptor polypeptides.[1] *See e.g.*, PCT/US02/32007 at pages 24-

25 and Table 1, and PCT/US03/25004, Figure 1. Moreover, in addition to Kobe and

Kajava, which provides a detailed structure-function review of leucine-rich repeats,

including how to identify leucine-rich repeat consensus sequences,[2] Applicants submit

---

[1] The Examiner asserts in the Office Action at page 6 that the incorporation by reference of PCT/US02/32007 and PCT/US03/25004 is improper because "[e]ssential material may be incorporated by reference, but only by way of an incorporation by reference to a U.S. patent or U.S. patent application publication." However, Applicants are not using the references to these two PCT applications as material essential to the application, but rather, to show the "state of the art" at the time the application was filed.

[2] Applicants respectfully resubmit that the "InterPro: IPR001611 Leucine-rich repeat" reference that the Examiner downloaded from the European Bioinformatics Institute website, www.ebi.ac.uk/interpro/lEntry?ac=IPR001611, also discusses the consensus sequence of leucine-rich

Atty. Dkt. No. 2681.0470001/EJH/SAC

herewith Fournier, A.E., *et al.*, Nature 409:341-46 (2001) ("Fournier *et al.*"; Exhibit A), as further evidence of the teachings of the prior art at the time of the invention.

Fournier *et al.* describes the isolation and characterization of Nogo receptor-1 and was cited in the Information Disclosure Statement submitted September 5, 2006, as NPL6. Fournier *et al.* states that "[t]he predicted [Nogo receptor-1] protein contains a signal sequence followed by eight leucine-rich-repeat (LRR) domains, an LRR carboxy-terminal flanking domain that is cysteine rich, a unique region and a glycosylphosphatidylinositol (GPI) anchorage site." Fournier *et al.*, p. 343. Figure 4a shows a schematic of these various motifs in Nogo receptor-1, and Figure 4b contains an alignment of the eight leucine-rich repeats with the Pfam ("Protein families database") consensus leucine-rich repeat. *Id.* Pfam is, and was at the time of Fournier *et al.*, a collection of protein domains and families made publicly available through DNA and protein sequence analysis databases, such as BLAST, that one of ordinary skill in the art could use to identify common protein motifs, such as the leucine-rich repeat, in a protein sequence.

(C) The claim interpretation that would be given by one possessing the ordinary level of skill in the pertinent art at the time the invention was made. Thus, when viewed with reference to the present specification and the teachings of the prior art, one of ordinary level of skill in the art at the time of the invention could readily ascertain the scope of the phrase "eight leucine-rich repeats" as used in claims 42 and 52, because "the components of the term have well-recognized meanings." *See Bancorp Services, L.L.C. v. Hartford Life Ins. Co.*, 359 F.3d 1367, 1372 (Fed. Cir. 2004) (holding that a claim

---

repeats, which could be used by one of skill in the art to identify eight leucine-rich repeats in soluble Nogo

term which was not defined or used in the specification was discernible and not indefinite). Accordingly, Applicants respectfully request that this rejection be reconsidered and withdrawn.

III. Rejection over Strittmatter (U.S. Pat. No. 7,119,165) in View of Strittmatter (J. Mol. Neurosci., 19:117-121 (2002)) Under 35 U.S.C. § 103(a) is Traversed

In section 7 of the Office Action at pages 6-14, the Examiner has maintained the rejection of claims 42-45, 47, 51-53, and 60 under 35 U.S.C. § 103(a) as allegedly being obvious over Strittmatter (U.S. Pat. No. 7,119,165) ("the '165 patent") in view of Strittmatter (J. Mol. Neurosci., 19:117-121 (2002)) ("Strittmatter"). Applicants respectfully disagree.

In proceedings before the Patent and Trademark Office, the Examiner bears the burden of establishing a *prima facie* case of obviousness based upon the prior art. *See In re Piasecki,* 745 F.2d 1468, 1471-73 (Fed. Cir. 1984). As set forth in *Graham v. John Deere Co. of Kansas City,* "[u]nder § 103, the scope and content of the prior art are to be determined; differences between the prior art and the claims at issue are to be ascertained; and the level of ordinary skill in the pertinent art resolved. Against this background the obviousness or nonobviousness of the subject matter is determined." 383 U.S. 1, 17 (1966). This has been the standard for 40 years, and remains the law today. *See KSR Int'l. Co. v. Teleflex Inc.,* 550 U.S. 398, 127 S. Ct. 1727 (2007). If, after these criteria are considered, the evidence indicates that the claimed invention is obvious over the prior art, it may be said that a *prima facie* case of obviousness has been established.

---

receptor-1. *See* page 2 of 5.

Atty. Dkt. No. 2681.0470001/EJH/SAC

In addition, the Examiner must show reasons, explicit or otherwise, that would compel one of ordinary skill in the art to combine the references in order to make and use the claimed invention. To determine whether there is "an apparent reason to combine" the known elements as an application claims,

> it will be necessary . . . to look to interrelated teachings of multiple patents; the effects of demands known to the design community or present in the marketplace; and the background knowledge possessed by a person having ordinary skill in the art. . . . To facilitate review, this analysis should be made explicit.

Id. at 1740-41; *see also* Memorandum from the United States Patent and Trademark Office, "Supreme Court decision on *KSR Int'l. Co. v. Teleflex, Inc.*," (May 3, 2007) ("The Court did not totally reject the use of 'teaching, suggestion, motivation' as a factor in the obviousness analysis. . . . [I]n formulating a rejection . . . based upon a combination of prior art elements, it remains necessary to identify the reason why a person of ordinary skill in the art would have combined the prior art elements in the manner claimed.").

Applicants assert that the Examiner has failed to establish a *prima facie* case of obviousness as discussed below. Applicants further assert that there is no apparent reason to combine the prior art references cited by the Examiner to arrive at the claimed invention and that there was no reasonable expectation of success at the time the invention was made.

Claims 42 and 52, and the claims depending therefrom, are directed to a method for reducing the levels of Aβ peptide in a mammalian brain and a method of treating a disease, disorder, or condition associated with plaques of Aβ peptide in a mammalian brain, comprising administering a therapeutically effective amount of a soluble Nogo receptor-1 polypeptide, wherein said soluble Nogo receptor-1 polypeptide comprises an

NT domain, eight leucine-rich repeats, and an LRRCT domain. Claim 52 further specifies that the polypeptide reduces plaque deposits. The '165 patent does not disclose, suggest, or otherwise contemplate these methods.

The '165 patent discloses polypeptides of Nogo receptor-1 wherein said polypeptides inhibit Nogo receptor-mediated neurite outgrowth inhibition. *See, e.g.*, the '165 patent at col. 3, lines 51-53, and col. 97, lines 42-45. In addition, the '165 patent broadly teaches a "method of treating a central nervous system disease, disorder or injury, e.g., spinal cord injury." S*ee, e.g., id.* at col. 4, lines 28-30. However, as the Examiner correctly points out, the '165 patent does not teach or suggest a method of reducing the levels of $A\beta$ peptide in a mammalian brain, nor does the '165 patent teach or suggest a method of treating a disease, disorder, or condition associated with plaques of $A\beta$ peptide in a mammalian brain, comprising administering a therapeutically effective amount of a soluble Nogo receptor-1 polypeptide, wherein said polypeptide reduces plaque deposits. Moreover, there is nothing in the '165 patent to suggest a relationship between Nogo receptor and $A\beta$ peptide, as the '165 patent is directed to, *inter alia*, the interaction between Nogo receptor and Nogo ligand, *e.g.*, for decreasing Nogo-dependent inhibition of axonal growth in CNS neurons. *See, e.g., id.* at col. 3, lines 45-53.

These deficiencies are not cured by the disclosure of Strittmatter. Strittmatter is directed to the physiologic role of Nogo ligand and Nogo receptor in the modulation of axonal growth. *See* Strittmatter, page 117, Abstract. While Strittmatter mentions the "generally accepted" pathology of Alzheimer's Disease (AD), "that neuronal loss is initiated by the accumulation of the β-amyloid ($A\beta$) peptide and that this results in cognitive dysfunction," Strittmatter contemplates the promotion of axonal growth as a

therapeutic approach for the recovery of lost function, <u>not</u> reducing Aβ peptide. *Id.* at page 117, left column. For example, Strittmatter states that "the identification of Nogo and NgR provides the opportunity for novel and rational therapeutics *to promote axonal growth* in the adult mammalian CNS. . . . Specifically, the goal is to develop *a method to block Nogo action* in vivo, and thereby allow functional axonal regeneration and plasticity." *Id.* at page 120, left column (emphases added). Promoting axonal growth and methods of blocking Nogo action using, *e.g.*, full-length Nogo receptor or a nondescript fragment thereof, does not obviate the subject matter of claims 42 and 52, and the claims depending therefrom, directed to a method of reducing the levels of Aβ peptide and a method of treating a disease, disorder, or condition associated with plaques of Aβ peptide in a mammalian brain, by reducing plaque deposits.

The Examiner maintains that one of ordinary skill would have been motivated to combine the teachings of the '165 patent and Strittmatter, with a reasonable expectation of success, because both of these references teach the promotion of axonal growth as a possible therapy for neurodegenerative diseases or disorder, using Nogo receptor. *See* Office Action, page 9. The Examiner continues by asserting that Strittmatter:

> indicates that in AD, it is generally accepted that neuronal loss is initiated by the accumulation of the β-amyloid peptide and that this results in cognitive dysfunction, one would necessarily expect to reduce the levels of Aβ peptide in the mammalian brain when the soluble NgR-1 polypeptide is administered to the mammalian patient population.

Id. As explained above, the Examiner's focus on axonal growth, which involves the Nogo ligand and Nogo receptor, is misplaced, as one of ordinary skill in the art would not have been motivated to administer a soluble Nogo receptor-1 polypeptide to reduce Aβ peptide levels or to treat a disease, disorder, or condition associated with plaques of

Aβ peptide in a mammalian brain, by reducing plaque deposits, based on the disclosure of methods of promoting axonal growth, even as the latter may pertain to AD therapy.[3]

Furthermore, the Examiner's statements that "one would necessarily expect to reduce the levels of Aβ peptide" and "[a]xonal growth would necessarily reduce the Aβ peptide levels in the brains of mammals being administered with NgR-1 polypeptide," seem to indicate that the Examiner has based her rejection of the present method claims on inherent obviousness. *Id.* at pages 9 and 14. Applicants respectfully wish to reiterate to the Examiner, however, that there is no such thing as inherent obviousness, since inherency and obviousness are different legal concepts. *See In re Spormann*, 363 F.2d 444 (C.C.P.A. 1966); *In re Rijckaert*, 9 F.3d 1531 (Fed. Cir. 1993). That which is inherent cannot be obvious, since inherent information "is not necessarily known . . . . [and] [o]bviousness cannot be predicated on what is unknown." *Spormann*, 363 F.2d at 448; *see also* M.P.E.P. § 2141.02 ("Obviousness cannot be predicated on what is not known at the time an invention is made, even if the inherency of a certain feature is later established."). Because the present rejection is based on obviousness, any contention by the Examiner that is based on the possible presence of inherent knowledge in Strittmatter must necessarily fail. Moreover, one of ordinary skill in the art at the time of the invention would not have expected soluble Nogo receptor-1 polypeptide to reduce the

---

[3] This distinction is further delineated in Strittmatter, which states that:

> if successful therapies are developed to delay or halt neuronal death in AD, then means to promote increased axonal growth and new synaptic connections from remaining cells should provide a mechanism for *recovery of lost function* as opposed to simply halting the progression of disease. The recent excitement surrounding the hypothesis that selective secretase inhibitors might limit Aβ production and neuronal loss emphasizes the need to develop therapeutics to *improve axonal sprouting and regeneration.*

levels of Aβ peptide because one of ordinary skill in the art would not have appreciated that Nogo receptor-1 interacted with Aβ peptide or its precursor protein, amyloid precursor protein (APP). As indicated in the present specification, Applicants were the first to elucidate and characterize this relationship. *See, e.g.,* the specification at page 17, line 10, through page 22, line 16 (Examples 1-6).

Therefore, Applicants submit that the combination of the '165 patent and Strittmatter does not disclose, suggest, or otherwise contemplate the presently claimed invention because neither reference provides any motivation, either explicit or implicit, to administer a soluble Nogo receptor-1 polypeptide in a method for reducing the levels of Aβ peptide in a mammalian brain or in a method for treating a disease, disorder, or condition associated with plaques of Aβ peptide in a mammalian brain, wherein the polypeptide reduces plaque deposits. Accordingly, a *prima facie* case of obviousness has not been established. In view of the foregoing remarks, reconsideration and withdrawal of the rejection under 35 U.S.C. § 103(a) is respectfully requested.

IV. *Statement of Substance of Interview*

Further to the Interview Summary mailed on April 22, 2009, Applicants submit the following Statement of Substance of the Interview in accordance with M.P.E.P. § 713.04. Applicants thank Examiner Julie Ha and Supervising Patent Examiner Cecilia Tsang for the courtesy of a personal interview held with Applicants' representatives, Shannon A. Carroll and Jeremiah Frueauf, on April 21, 2009, regarding the present

---

Strittmatter, page 117 (emphases added). Thus, Strittmatter clearly contemplates the use of Nogo receptor in promoting axonal growth as a mechanism of recovery of lost function but <u>not</u> as a mechanism of delaying or halting neuronal death in AD, e.g., by limiting Aβ peptide production.

Atty. Dkt. No. 2681.0470001/EJH/SAC

application. During that interview, Applicants' representatives discussed the 35 U.S.C. §§ 112, second paragraph, and 103(a) rejections from the presently outstanding Office Action. Applicants' representatives discussed Fournier *et al.* (Exhibit A) and schematics representing the signal transduction pathways of Nogo receptor in the inhibition of axonal growth and in the reduction of Aβ peptide. Examiner Ha and Supervising Patent Examiner Tsang agreed to consider Applicant's claims in view of the discussion.

The Examiner is invited to contact the Applicants' undersigned representatives at the number provided with any inquiries regarding this Statement.

Conclusion

All of the stated grounds of rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

    Prompt and favorable consideration of this Reply is respectfully requested.

        Respectfully submitted,

        STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

        Shannon A. Carroll, Ph.D.
        Attorney for Applicants
        Registration No. 58,240

Date: _April 30, 2009_

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
969894_2.DOC

letters to nature

Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration

Alyson E. Fournier*, Tadzia GrandPre* & Stephen M. Strittmatter

Department of Neurology and Section of Neurobiology, Yale University School of Medicine, P.O. Box 208018, New Haven, Connecticut 06520, USA
* These authors contributed equally to this work

Nogo has been identified as a component of the central nervous system (CNS) myelin that prevents axonal regeneration in the adult vertebrate CNS. Analysis of Nogo-A has shown that an axon-inhibiting domain of 66 amino acids is expressed at the extracellular surface and at the endoplasmic reticulum lumen of transfected cells and oligodendrocytes[1]. The acidic amino terminus of Nogo-A is detected at the cytosolic face of cellular membranes[1] and may contribute to inhibition of axon regeneration at sites of oligodendrocyte injury[2,3]. Here we show that the extracellular domain of Nogo (Nogo-66) inhibits axonal extension, but does not alter non-neuronal cell morphology. In con-

trast, a multivalent form of the N terminus of Nogo-A affects the morphology of both neurons and other cell types. Here we identify a brain-specific, leucine-rich-repeat protein with high affinity for soluble Nogo-66. Cleavage of the Nogo-66 receptor and other glycophosphatidylinositol-linked proteins from axonal surfaces renders neurons insensitive to Nogo-66. Nogo-66 receptor expression is sufficient to impart Nogo-66 axonal inhibition to unresponsive neurons. Disruption of the interaction between Nogo-66 and its receptor provides the potential for enhanced recovery after human CNS injury.

Assays of Nogo-A function have included growth-cone collapse, neurite outgrowth and fibroblast spreading with substrate-bound and soluble protein preparations[1-5]. The extracellular Nogo-66 domain collapses dorsal root ganglion (DRG) axonal growth cones and inhibits neurite outgrowth[1]. In assays of 3T3 fibroblast morphology, substrate-bound Nogo-66 does not inhibit spreading (Fig. 1b, c). As NI-250 preparations and full-length Nogo-A are non-permissive for 3T3 spreading[2,5], we considered whether different domains of Nogo might subserve this *in vitro* activity. Two pieces of evidence indicate that the N terminus of Nogo-A may contribute to inhibition of axonal regeneration: antibodies directed against this domain reduce the non-permissive qualities of CNS myelin[2]; and this domain alone can reduce cerebellar neurite outgrowth[3].


Figure 1 Comparison of Nogo domains. **a**, The Nogo proteins. **b**, NIH 3T3 fibroblasts cultured on different surfaces. Scale bar, 40 μm. **c**, 3T3 fibroblast spreading (> 1,200 μm²) measured on Nogo-coated surfaces (black) or with soluble 100 nM Nogo preparations (blue). AM, Amino-Nogo; AM + Myc, Amino-Nogo pre-incubated with anti-Myc antibody; AM + Myc + Mo, Amino-Nogo plus anti-Myc pre-incubated with anti-

mouse IgG; Myc + Mo, anti-Myc antibody plus anti-mouse IgG antibody. **d**, Chick E12 DRGs cultured on surfaces coated with different proteins (substrate-bound) or soluble proteins (soluble). Scale bar, 40 μm. Neurite outgrowth on Nogo-coated surfaces or with soluble Nogo preparations was quantified for E13 DRG (**e**) or cerebellar granule cell cultures (**f**).

 341

To facilitate a comparison between different Nogo-A domains, we expressed the N-terminal 1,040-amino-acid fragment (Amino-Nogo), as a MycHis-tagged protein in HEK293T cells. As predicted from immunolocalization studies[1], the protein is present in cytosolic fractions. Surfaces coated with purified Amino-Nogo protein fail to support 3T3 fibroblast spreading (Fig. 1b, c). Similar results are observed for a kidney-derived cell line, COS-7 (data not shown). The N-terminal domain therefore seems to account for the effects of full-length Nogo-A on fibroblasts.

We also exposed DRG cultures to Amino-Nogo protein (Fig. 1d, e). The fibroblast-like cells in the DRG culture do not spread on the Amino-Nogo substrate. Furthermore, axonal outgrowth is reduced to low levels on surfaces coated with Amino-Nogo. Thus, although the Nogo-66 effects are neural-specific, the inhibitory action of the Amino-Nogo domain is more generalized. When presented in soluble form at 100 nM, the Nogo-66 polypeptide collapses chick E12 DRG growth cones and nearly abolishes axonal extension[1]. In marked contrast, the soluble Amino-Nogo protein seems inactive, and does not significantly modulate DRG growth-cone morphology, DRG axonal extension, or non-neuronal cell spreading (Fig. 1c–e; and data not shown). Cerebellar granule neurons have been studied previously, and soluble Amino-Nogo was presented as an Fc fusion protein—presumably in dimeric form[3]. We therefore considered whether these differences might explain the inactivity of soluble Amino-Nogo.

The response of mouse P4 cerebellar granule neurons and chick E13 DRG neurons to Nogo preparations is indistinguishable (Fig. 1f). Amino-Nogo dimerized with anti-Myc antibody inhibits 3T3 and COS-7 spreading (Fig. 1c; and data not shown) and tends to reduce cerebellar axon outgrowth (Fig. 1f). When further aggregated by the addition of anti-mouse IgG antibody, Amino-Nogo significantly reduces both DRG and cerebellar axon outgrowth (Fig. 1e, f). Although the Amino-Nogo protein is quite acidic, electrostatic charge alone does not account for its inhibitory effects, as poly-Asp does not alter cell spreading or axonal outgrowth (Fig. 1c, e). Both of the Nogo domains can potently inhibit

axon growth under certain circumstances, but they possess different mechanisms of action.

On the basis of the neuronal-selective action of Nogo-66 and its high potency as a soluble monomeric ligand, we sought to identify a neuronal receptor for this Nogo domain. We chose the placental alkaline phosphatase (AP) fusion protein approach[6]. An AP–Nogo fusion protein can be purified from the conditioned medium of transfected cells in milligram amounts. This protein is biologically active as a growth-cone-collapsing agent, with an effective concentration for half-maximal response (EC_{50}) of 1 nM (Fig. 2). AP–Nogo is slightly more potent than glutathione S-transferase (GST)–Nogo-66, perhaps because the protein is synthesized in a eukaryotic

Figure 2 Ligand-binding assay for axonal Nogo-66 receptors. **a**, Dissociated chick E12 DRG neurons incubated with 10 nM AP–Nogo or 10 nM AP–Nogo + 160 nM GST–Nogo-66, and stained for bound AP. Scale bar, 40 μm. **b**, Potency of AP–Nogo and GST–Nogo in E12 chick DRG growth-cone-collapse assays. **c**, AP–Nogo binding to DRG neurons measured as a function of AP–Nogo concentration. Error bars are from individual measurements in one of six experiments with similar results. **d**, Replotted data from **c**. K_d, 3 nM.

Figure 3 Nogo-66 binding to COS-7 cells expressing the Nogo-66 receptor. **a**, COS-7 cells transfected with an expression vector encoding mouse NgR or a vector control. Two days later, binding of AP–Nogo or AP was assessed. Scale bar, 200 μm. **b**, AP–Nogo binding to NgR expressing COS-7 cells measured as a function of AP–Nogo concentration. Error bars are from individual measurements in one of six experiments with similar results. **c**, Replotted data from **b**. K_d, 7 nM.

342 NATURE | VOL 409 | 18 JANUARY 2001 | www.nature.com

rather than a prokaryotic cell. AP–Nogo binds to saturable, high-affinity sites on chick E12 DRG axons. Binding is blocked by excess GST–Nogo-66, consistent with competitive binding to a neuronal receptor site. As the apparent dissociation constant (K_d, 3 nM) for these sites is close to the EC_{50} of AP–Nogo in the collapse assay, the sites are probably physiologically relevant Nogo-66 receptors.

We used the AP–Nogo binding assay for expression cloning of a Nogo-66 receptor. Pools of a complementary DNA expression library from the adult brain of a mouse, representing 250,000 independent clones, were transfected into non-neuronal COS-7 cells. Non-transfected COS-7 cells do not bind AP–Nogo (Fig. 3), but transfection with two pools of 5,000 clones showed a few cells with strong AP–Nogo binding. Single cDNA clones encoding a Nogo-binding site were isolated by sib selection from each of the two positive pools. The two independently isolated clones are identical to one another except for a 100 base-pair (bp) extension of the 5′ untranslated region in one clone. Transfection of these cDNAs into COS-7 cells yields a binding site with an affinity for AP–Nogo similar to that observed in E13 DRG neurons; the K_d for binding is about 7 nM (Fig. 3). AP alone does not bind with any detectable affinity to these transfected cells, indicating that the affinity is due to the 66 residues derived from Nogo. Furthermore, excess GST–Nogo-66 displaces AP–Nogo from these sites.

The cDNA directing the expression of a Nogo-binding site in COS-7 cells encodes a protein of 473 amino acids, which we have called Nogo-66 receptor (NgR). The predicted protein contains a signal sequence followed by eight leucine-rich-repeat (LRR) domains, an LRR carboxy-terminal flanking domain that is cysteine rich, a unique region and a glycosylphosphatidylinositol (GPI) anchorage site (Fig. 4). There is no full-length cDNA in GenBank with significant nucleotide sequence similarity (expectation value, $E \leq 0.05$ by BLASTN analysis); several mouse and human expressed sequence tags (ESTs) match fragments of the sequence precisely. In the LRR domains, there is moderate amino-acid sequence similarity

(up to 35% amino-acid identity) to many other proteins containing this domain. The LRR proteins sharing the greatest sequence similarity are slit1–3 and the acid-labile subunit of the insulin-like growth-factor-binding protein complex. We have identified a human homologue of the mouse NgR cDNA that shares 89% amino-acid identity. The existence of this cDNA was predicted from the mouse cDNA structure and from analysis of human genomic sequence deposited in GenBank as part of the human genome sequencing effort. The exons of the human NgR gene on chromosome 22q11 are separated by nearly 30 kilobases (kb), and the messenger RNA was not previously recognized in the genomic sequence. The predicted protein structure is consistent with a cell-surface protein capable of binding Nogo.

We next verified that the protein was associated with the cell surface through a GPI linkage. A Myc-tagged version of NgR protein with a relative molecular mass of 85,000 (M_r 85K) is found in particulate fractions, and can be released by phosphatidylinositol-specific phospholipase C (PI-PLC) treatment, as expected for a GPI-linked protein (Fig. 4c). The GPI-linked nature of the protein suggests that there may be a second receptor subunit that spans the plasma membrane and mediates Nogo-66 signal transduction.

The simplest model for NgR expression mediating AP–Nogo binding is that the two proteins bind directly to one another. To assess their physical interaction, we incubated extracts from Myc–NgR expressing HEK293T cells with resin-bound GST–Nogo-66 or GST (Fig. 4d). NgR is selectively retained by the Nogo-containing resin, verifying that the two proteins associate as part of a protein complex.

The distribution of the mRNA expression for the NgR is consistent with a function for the protein in regulating axonal regeneration and plasticity in the adult CNS. Northern analysis shows a single band of 2.3 kb in the adult brain, indicating that the isolated NgR clone is full length (Fig. 5). Low levels of this mRNA are observed in heart and kidney but not in other peripheral tissues. In


a Signal LRR LRRCT TM/GPI

473aa

b

```
Pfam Cons.    nLeeLdLsnN..LtslppglfsnLp
NgR 58-81     SSQRIFLHGNR.ISHVPAASFQSCR
NgR 82-105    NLTILWLHSNA.LARIDAAAFTGLT
NgR 106-130   LLEQLDLSDNAQLHVVDPTTFHGLG
NgR 131-154   HLHTLHLDRCG.LRELGPGLFRGLA
NgR 155-178   ALQYLYLQDNN.LQALPDNTFRDLG
NgR 179-202   NLTHLFLHGNR.IPSVPEHAFRGLH
NgR 203-226   SLDRLLLHQNH.VARVHPHAFRDLG
NgR 227-250   RLMTLYLFANN.LSMLPAEVLMPLR
```

c — PLC   + PLC
S P   S P

d Resin
Input Nogo None GST

Figure 4 Structure of Nogo-66 receptor. **a**, Main structural features of the NgR protein. Signal, signal peptide; LRR, leucine-rich repeat; LRRCT, LRR C-terminal domain; TM/GPI, predicted transmembrane/glycosylphosphatidylinositol linkage. **b**, Amino-acid sequence of the LRRs is aligned with the Pfam consensus leucine-rich repeat. **c**, Extracts from Myc– NgR-expressing cells treated with or without PI-PLC, and soluble (S) or particulate (P) fractions were analysed by anti-Myc immunoblot. **d**, Myc–NgR PI-PLC extract (Input) was incubated with glutathione-coupled GST–Nogo-66 that contained agarose (Nogo) or buffer (None), or GST (GST). Bound protein was detected by anti-Myc immunoblot.

 343

the brain, expression is widespread and the areas richest in grey matter express the highest levels of the mRNA by northern analysis (data not shown). *In situ* hybridization shows NgR expression in cerebral cortical neurons, hippocampal neurons, cerebellar Purkinje cells and pontine neurons (Fig. 5b). NgR is expressed in those cerebral cortex pyramidal neurons whose regeneration is enhanced by IN-1 treatment[7], and in those cerebellar Purkinje neurons whose sprouting is increased by anti-Nogo-A antibody[8]. Nogo-66 receptor mRNA is not detected in white matter (Fig. 5b), where Nogo-A is expressed by oligodendrocytes[1,2].

To characterize further the expression of the NgR protein, we developed an antiserum to a GST–NgR fusion protein. This antiserum detects selectively an 85K protein in NgR-expressing HEK293T cells (Fig. 5c), and specifically stains COS-7 cells expressing NgR (Fig. 5d). Immunohistological staining of chick embryonic spinal-cord cultures localizes the protein to axons, consistent with the mediation of axon-outgrowth inhibition induced by Nogo-66 (Fig. 5d). NgR expression is not found in the O4-positive oligodendrocytes (Fig. 5d) that express Nogo[1]. Immunoreactive 85K protein is expressed in Nogo-66-responsive neuronal preparations from chick E13 DRGs, but to a much lesser extent in weakly responsive tissue from chick E7 DRGs and chick E7 retina (Fig. 5c). Overall, the pattern of NgR expression is consistent with the protein's mediating Nogo-66 axon inhibition.

We next investigated whether the NgR protein is necessary for Nogo-66 action and not simply a binding site with a function unrelated to inhibition of axonal outgrowth. A first prediction is that PI-PLC treatment to remove GPI-linked proteins from the neuronal surface will render neurons insensitive to Nogo-66. This is true for chick E13 DRG neurons: PI-PLC treatment abolishes both AP–Nogo binding (data not shown) and growth-cone collapse induced by GST–Nogo-66 (Fig. 6a, c). As a control, Sema3A responses in the parallel cultures are not altered by PI-PLC treatment. However, PI-PLC treatment is expected to remove a number of proteins from the axonal surface, so this result leaves open the possibility that other GPI-linked proteins are mediating the Nogo-66 response in untreated cultures.

To show that NgR is capable of mediating Nogo-66 inhibition of axon outgrowth, we expressed the protein in neurons lacking a Nogo-66 response. We examined both DRG and retinal neurons from E7 chick embryos. The Nogo responses in the DRG neurons from this developmental stage are weak[1], but slight responses can be detected in some cultures (data not shown). E7 retinal ganglion cell growth cones are uniformly insensitive to growth-cone collapse induced by Nogo-66 (Fig. 6b, d), do not bind AP–Nogo (data not shown), and do not exhibit 85K anti-NgR immunoreactive protein (Fig. 5c). Expression of NgR in these neurons by infection with recombinant herpes simplex virus (HSV) preparations renders the axonal growth cones of the retinal ganglion cell sensitive to Nogo-66-induced collapse. Infection with a control PlexinA1-expressing


Figure 5 Distribution of Nogo-66 receptor expression. **a**, Northern analysis of NgR in mouse. The positions of RNA size markers (kb) are at the left. **b**, NgR *in situ* hybridization for adult mouse brain. II, IV, cerebral cortical layers; Py, cortical pyramidal cell layer; m, molecular, p, Purkinje cell, and g, granule cell layer of the cerebellum; dg, dentate gyrus of the hippocampus; pn, pontine nucleus of the pons; asterisk, descending pyramidal tract; so, superior olivary nucleus. Scale bar, 500 μm. **c**, Anti-NgR immunoblot analysis of membrane fractions from indicated cells or chick tissues. **d**, COS-7 cells expressing Myc–NgR or chick E5 spinal-cord explants (8 d *in vitro*) were stained with anti-NgR, anti-Myc or the oligodendrocyte-specific O4 antibody. Scale bars, 40 μm (top); 80 μm (bottom).

control HSV preparation does not alter Nogo responses. Together, these data indicate that the Nogo receptor identified here may participate in Nogo-66 inhibition of axon regeneration.

Our study identifies a GPI-linked, LRR protein as a receptor that mediates Nogo-66 inhibition of axonal outgrowth. The expression of this receptor produces a binding site for Nogo-66 with an affinity similar to that for growth-cone collapse induced by Nogo-66, and the two proteins physically associate with one another. Furthermore, expression of NgR protein is sufficient to convert axonal growth cones from a Nogo-66-insensitive to a Nogo-66-responsive state. It is clear that the extracellular 66-residue domain of Nogo and the N-terminal Nogo-A domain have different cellular effects. The biological significance of the Nogo-66 domain is supported by its neuronal specificity, its potent action as a monomeric ligand and the current identification of a high-affinity neuronal receptor for this

fragment. The NgR identified here is GPI-linked to the cell surface. This indicates that it may function as part of a receptor complex, serving as the primary Nogo-66 binding site while associated transmembrane receptor subunits are responsible for signal transduction. The Amino-Nogo domain is intracellular, has actions that are not cell-type specific, and functions only in a multivalent state. The two domains may act synergistically to inhibit outgrowth in the injured CNS. Evidence indicates that Nogo expression in the adult brain by oligodendrocytes may serve to limit axonal plasticity and regeneration after injury[9]. Therefore, the current identification of a receptor mediating Nogo-66 action should greatly facilitate the development of agents with pharmaceutical potential in a diverse group of neurological conditions, such as spinal-cord injury, brain trauma, stroke affecting white matter and chronic, progressive multiple sclerosis. ☐


Figure 6 Nogo-66 receptor mediates growth-cone collapse by Nogo-66. a, Chick E12 DRG explants exposed to Nogo-66 after pretreatment with PIPLC or buffer. Scale bar, 40 μm. b, E7 retinal ganglion cell explants infected with HSV-PlexinA1 or HSV-Myc–NgR, and incubated with or without Nogo-66. Scale bar, 25 μm. c, Growth-cone-collapse

measurements from experiments as in a are shown. DRG cultures treated with or without PI-PLC before exposure to 30 nM GST–Nogo-66 or 100 pM Sema3A. d, Quantification of growth-cone collapse in uninfected or viral-infected E7 retinal neurons as in b.

Methods

Nogo recombinant proteins

To express Amino-Nogo, the human Nogo-A cDNA for residues 1–1,040 was ligated into pcDNA3.1MycHis (Invitrogen, Burlingame, California) with an in-frame Myc-His tag. We transfected this plasmid into HEK293T cells and Amino-Nogo was purified with a Ni^{2+} resin[10]. The human Nogo-66 sequence was ligated into pcAP-5 (ref. 10) in frame with the signal sequence, $6 \times$ His tag and placental AP coding region. This plasmid was transfected into HEK293 cells, and secreted AP–Nogo was purified by Ni^{2+} affinity chromatography. GST–Nogo-66 has been described[1].

Nogo-66 receptor binding assays and expression cloning

To detect AP–Nogo binding, cultures were washed with Hanks balanced salt solution containing 20 mM sodium HEPES, pH 7.05, and 1 mg ml^{-1} bovine serum albumin (BSA) (HBH). The plates were then incubated with AP–Nogo in HBH for 2 h at 23 °C. We detected and quantified bound AP–Nogo as for AP–Sema3A[11]. For saturation analysis of AP–Nogo bound to COS-7 cells, bound AP–Nogo protein was eluted with 1% Triton X-100. After heat inactivation of endogenous AP, we measured AP–Nogo using p-nitrophenyl phosphate as substrate.

For expression cloning of a Nogo-66 receptor, pools of 5,000 arrayed clones from a mouse adult-brain cDNA library (Origene Technologies, Rockville, Maryland) were transfected into COS-7 cells, and AP–Nogo binding was assessed. We isolated single NgR cDNA clones by sib selection and sequenced them. A Myc–NgR vector was created in pSecTag2-Hygro (Invitrogen) using the signal peptide of pSecTag2 fused to Myc and residues 27–473 of NgR. Human NgR cDNA was predicted from a human genomic cosmid sequence (AC007663). Oligonucleotide primers based on the predicted human cDNA amplified the cDNA from a human adult-brain cDNA library (Origene Technologies).

To assess binding of Myc–NgR to the cell membrane, particulate fractions were treated with or without 5 U PI-PLC (Sigma, St. Louis, MO) per mg of HEK293T cell protein for 1 h at 30 °C in HBH. After centrifugation at 100,000g for 1 h, we analysed equal proportions of the soluble and particulate fractions. To assess the physical interaction of NgR with Nogo-66, we incubated the PI-PLC extract (50 µg total protein) with 10 µg GST–Nogo-66 or buffer, or 10 µg GST for 1 h at 23 °C. We added glutathione-coupled agarose to bind GST and associated proteins. We analysed bound proteins by anti-Myc immunoblot.

RNA analysis

For northern blots, 1 µg poly(A)$^+$ RNA from each adult mouse tissue on a nylon membrane (Origene Technologies) was hybridized with a full-length ^{32}P-labelled probe[1,12]. We used digoxegenin-labelled riboprobes (nucleotides 1–1,222) and adult mouse brain sections[1,12] for in situ hybridization. The sense probe produced no signal.

Nogo-66 receptor antibodies

A GST–NgR (residues 27–447) fusion protein was purified from Escherichia coli and used to immunize rabbits. We diluted immune serum 3,000-fold for immunoblots and 1,000-fold for immunohistology on tissue-culture samples that had been fixed by formalin. Staining of tissue was totally abolished by addition of 5 µg ml^{-1} GST–NgR.

Cell spreading, neurite outgrowth and viral infection

To measure spreading rates, subconfluent NIH 3T3 fibroblasts or COS-7 cells were plated for 1 h in serum-containing medium before fixation and staining with rhodamine-phalloidin. Glass coverslips were precoated with 100 µg ml^{-1} poly-L-lysine, washed, and then 3 µl drops of PBS containing 15 pmol Amino-Nogo, 15 pmol GST–Nogo-66, 15 pmol poly-Asp (M_r 35 K, Sigma), or no protein were spotted and dried. We added soluble Nogo protein preparations (100 nM) at the time of plating. Amino-Nogo was added alone or after a pre-incubation with a twofold molar excess of anti-Myc 9E10 antibody, or with a twofold excess of anti-Myc plus a twofold excess of purified goat anti-mouse IgG.

Chick E5 spinal cord, chick E7–E13 DRG, chick E7 retina and mouse P4 cerebellar neuron culture, growth-cone-collapse assays and neurite-outgrowth assays have been described[1,10–13]. Here, outgrowth from dissociated neurons was assessed after 12–24 h. For the substrate-bound experiments, glass chamber slides were coated with 100 µg ml^{-1} poly-L-lysine, washed, and then 3 µl drops of PBS containing 15 pmol Amino-Nogo, 15 pmol GST–Nogo-66, 15 pmol poly-Asp, or no protein were spotted and dried. After three PBS washes, we coated slides with 10 µg ml^{-1} laminin. After aspiration of laminin, dissociated neurons were added. For the soluble Nogo experiments, slides were coated with poly-L-lysine and laminin in the same fashion, and then 100 nM Amino-Nogo, 100 nM clustered Amino-Nogo, or 100 nM GST–Nogo-66 was added to the culture medium at the time of plating. After 1 d in vitro, some DRG explants were treated for 30 min with 1 unit ml^{-1} PI-PLC (Sigma) before the growth-cone-collapse assay.

An HSV-Myc–NgR stock was prepared as described[10]. We infected E7 retinal explants for 24 h. We stained some cultures infected with HSV-Myc–NgR with anti-Myc antibody to verify protein expression. Error bars reflect the s.e.m. from 4–8 determinations.

1. GrandPre, T., Nakamura, F., Vartanian, T. & Strittmatter, S. M. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature 403, 439–444 (2000).
2. Chen, M. S. et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 403, 434–439 (2000).
3. Prinjha, R. et al. Inhibitor of neurite outgrowth in humans. Nature 403, 383–384 (2000).
4. Schwab, M. & Caroni, P. Oligodendrocytes and CNS myelin are non-permissive substrates for neurite growth and fibroblast spreading in vitro. J. Neurosci. 8, 2381–2393 (1988).
5. Caroni, P. & Schwab, M. E. Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J. Cell Biol. 106, 1281–1288 (1988).
6. Flanagan, J. G. & Leder, P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 63, 185–194 (1990).
7. Schnell, L. & Schwab, M. E. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 343, 269–272 (1990).
8. Buffo, A. et al. Application of neutralizing antibodies against NI-35/250 myelin-associated neurite growth inhibitory proteins to the adult rat cerebellum induces sprouting of uninjured Purkinje cell axons. J. Neurosci. 20, 2275–2286 (2000).
9. Thallmair, M. et al. Neurite growth inhibitors restrict plasticity and functional recovery following corticospinal tract lesions. Nature Neurosci. 1, 124–131 (1998).
10. Nakamura, F., Tanaka, M., Takahashi, T., Kalb, R. G. & Strittmatter, S. M. Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron 21, 1093–1100 (1998).
11. Takahashi, T., Nakamura, F., Jin, Z., Kalb, R. G. & Strittmatter, S. M. Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nature Neurosci. 1, 487–493 (1998).
12. Goshima, Y., Nakamura, F., Strittmatter, P. & Strittmatter, S. M. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 376, 509–514 (1995).
13. Huang, D. W., McKerracher, L., Braun, P. E. & David, S. A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron 24, 639–647 (1999).

Maize *yellow stripe1* encodes a membrane protein directly involved in Fe(III) uptake

Catherine Curie*†, Zivile Panaviene†‡, Clarisse Loulergue*, Stephen L. Dellaporta§, Jean-Francois Briat* & Elsbeth L. Walker‡

* Biochimie et Physiologie Moléculaire des Plantes, Centre National de la Recherche Scientifique (Unité Mixte de Recherche 5004), Institut National de la Recherche Agronomique, Université Montpellier 2 et École Nationale Supérieure d'Agronomie, Place Viala, F-34060 Montpellier cedex 1, France
‡ Biology Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
§ Molecular, Cellular & Developmental Biology Department, Yale University, New Haven, Connecticut 06520-8104, USA
† These authors contributed equally to this work

Frequently, crop plants do not take up adequate amounts of iron from the soil, leading to chlorosis, poor yield and decreased nutritional quality. Extremely limited soil bioavailability of iron has led plants to evolve two distinct uptake strategies: chelation, which is used by the world's principal grain crops[1,2]; and reduction, which is used by other plant groups[3–5]. The chelation strategy involves extrusion of low-molecular-mass secondary amino acids (mugineic acids) known as 'phytosiderophores', which chelate sparingly soluble iron[6]. The Fe(III)-phytosiderophore complex is then taken up by an unknown transporter at the root surface[7,8]. The maize *yellow stripe1* (*ys1*) mutant is deficient in Fe(III)-phytosiderophore uptake[7–10], therefore YS1 has been suggested to be the Fe(III)-phytosiderophore transporter. Here we show that *ys1* is a membrane protein that mediates iron uptake. Expression of YS1 in a yeast iron uptake mutant restores growth specifically on Fe(III)-phytosiderophore media. Under iron-deficient conditions, *ys1* messenger RNA levels increase in both roots and shoots.